search
Back to results

Clinical Evaluation of Acuity 200 (Fluoroxyfocon A) RGP Contact Lens (Acuity 200)

Primary Purpose

Refractive Errors

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Acuity 200 (Fluoroxyfocon A) contact lens
Acuity 100 (Hexafocon A) contact lens
Sponsored by
Acuity Polymers, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Refractive Errors focused on measuring refractive, permeable, lens, rigid, gas, myopia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Prior to being considered eligible to participate in this study, each subject MUST:

  • Be at least 18 years of age as of the date of evaluation.
  • Have:

    • read the Informed Consent,
    • been given an explanation of the Informed Consent,
    • indicated an understanding of the Informed Consent and
    • signed the Informed Consent Form.
  • Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
  • Be a current contact lens wearer.
  • Possess wearable and visually functional eyeglasses.
  • Be in good general health, based on his/her knowledge.
  • Require spectacle lens powers between +10.00 and -10.00 diopters sphere with no more than 2.5 diopters of spectacle refractive astigmatism and be willing to wear lenses in both eyes.
  • Have manifest refraction visual acuity equal to or better than 0.10 log MAR (20/25 Snellen) in each eye.

Exclusion Criteria:

Subjects may not be enrolled into the study if ANY of the following apply:

  • Subject is wearing lenses in a mono-vision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may NOT wear mono-vision lenses at any time during the study as it will interfere with the distance visual acuity measurement.
  • Subject appears to exhibit poor personal hygiene (that in the investigator's opinion might prevent safe contact lens wear).
  • Subject is currently or within 30 days prior to this study has been an active participant in another clinical study.
  • Subject is currently pregnant (to the best of the subject's knowledge), is planning a pregnancy within the next 3 months or is lactating.
  • Subject is a member, relative or household member of the office staff, including the investigator(s).
  • Subject has a known sensitivity to ingredients used in contact lens care products or over-the-counter lubricants and artificial tears.
  • Subject has undergone refractive surgery or is currently receiving or has previously received orthokeratology treatment.
  • Subject is aphakic or pseudophakic.
  • Subject has ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome lupus erythematosus, scleroderma, keratoconus or type II diabetes.
  • Subject has 2.5 diopters or great of corneal astigmatism.
  • Use of ocular medications for any reason or systemic medications which might interfere with contact lens wear.
  • A known history of corneal hypoesthesia (reduced corneal sensitivity).
  • Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

    • History of corneal ulcer, corneal infiltrates or fungal infections
    • Corneal scars within the visual axis
    • Pterygium
    • Dry eye symptoms with decrease tear levels and punctate staining ≥ Grade 2
    • Neovascularization or ghost vessels ≥l.5 mm in from the limbus
    • Seborrhoeic eczema, seborrhoeic conjunctivitis
    • History of papillary conjunctivitis that has interfered with lens wear or a current condition of Grade 2 (Mild) or greater
  • Clinically significant (Grade 3 or 4) anterior segment abnormalities or any infection of the eye, lids, or associated structures.
  • The investigator for any reason considers that it is not in the best interest of the subject to participate in the study.

To be eligible to be randomized for study product trial a subject must have ALL of the inclusion criteria and NONE of the exclusion criteria present. To be eligible for lens dispensing, the subject's study device contact lens visual acuity must be equal to or better than 0.20 log MAR (20/32 Snellen) in each eye

-

Sites / Locations

  • Ala Mona Advanced Eye Clinic
  • Cornea and Contact Lens Institute of Minnesota
  • Reed Eye Associates

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Acuity 200 contact lens

Acuity 100 contact lens

Arm Description

Rigid gas permeable contact lens for daily wear, fluoroxyfocon A

Rigid gas permeable contact lens for daily wear, hexafocon A

Outcomes

Primary Outcome Measures

Visual Acuity
Comparison of the corrected visual acuity (logMAR) between the Test and Control lens. The working hypothesis is that the visual acuity results will be substantially equivalent between the Test and the Control lenses.
Slit Lamp Exam Observations
Comparison of slit lamp exam findings (scored from 0-4) between Test and Control arms. The working hypothesis is that the findings will be substantially equivalent between the Test and the Control lenses.
Adverse Events
Comparison of the number of device related adverse events in the Test and Control arms. The working hypothesis is that the number of adverse events will be substantially equivalent between the Test and the Control lenses.

Secondary Outcome Measures

Subjective Symptoms
Comparison of subjective symptoms (scored from 0-5) between Test and Control arms. The working hypothesis is that the symptoms will be substantially equivalent between the Test and the Control lenses.

Full Information

First Posted
May 30, 2019
Last Updated
May 11, 2020
Sponsor
Acuity Polymers, Inc.
Collaborators
Andre Vision and Device Research
search

1. Study Identification

Unique Protocol Identification Number
NCT03971227
Brief Title
Clinical Evaluation of Acuity 200 (Fluoroxyfocon A) RGP Contact Lens
Acronym
Acuity 200
Official Title
Clinical Evaluation of Safety and Effectiveness for the Acuity 200 (Fluoroxyfocon A) Rigid Gas Permeable Contact Lens
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
April 1, 2019 (Actual)
Primary Completion Date
March 19, 2020 (Actual)
Study Completion Date
March 19, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Acuity Polymers, Inc.
Collaborators
Andre Vision and Device Research

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this clinical investigation is to collect valid scientific safety and effectiveness data on the Acuity 200 (fluoroxyfocon A) Rigid Gas Permeable Contact Lens, manufactured from a newly developed rigid gas permeable material that is highly permeable to oxygen. The clinical performance data reported from this study is intended to be submitted to the U.S. Food and Drug Administration Center for Devices and Radiological Health (CDRH) in support of a 510(k) premarket notification.
Detailed Description
This is an open-label, multi-center, randomized concurrent-control study with the treatment duration of 90 days. Subjects will be recruited into the study based upon the inclusion and exclusion criteria provided. Eligible subjects will be examined for baseline evaluation and lens fitting. Up to sixty (60) subjects will wear the test contact lenses for daily wear and up to twenty-eight (28) subjects will wear the control contact lenses. The subjects will attend seven scheduled study visits and will undergo standard ophthalmic evaluation for contact lens care. The subjects will be followed for a period of three months (90 days) following dispensing of the Test and Control Device.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Refractive Errors
Keywords
refractive, permeable, lens, rigid, gas, myopia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This is an open-label, multi-center, randomized concurrent-control study with the treatment duration of 90 days.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
74 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Acuity 200 contact lens
Arm Type
Experimental
Arm Description
Rigid gas permeable contact lens for daily wear, fluoroxyfocon A
Arm Title
Acuity 100 contact lens
Arm Type
Active Comparator
Arm Description
Rigid gas permeable contact lens for daily wear, hexafocon A
Intervention Type
Device
Intervention Name(s)
Acuity 200 (Fluoroxyfocon A) contact lens
Intervention Description
Daily wear rigid gas permeable contact lens
Intervention Type
Device
Intervention Name(s)
Acuity 100 (Hexafocon A) contact lens
Intervention Description
Daily wear rigid gas permeable contact lens
Primary Outcome Measure Information:
Title
Visual Acuity
Description
Comparison of the corrected visual acuity (logMAR) between the Test and Control lens. The working hypothesis is that the visual acuity results will be substantially equivalent between the Test and the Control lenses.
Time Frame
90 days
Title
Slit Lamp Exam Observations
Description
Comparison of slit lamp exam findings (scored from 0-4) between Test and Control arms. The working hypothesis is that the findings will be substantially equivalent between the Test and the Control lenses.
Time Frame
90 days
Title
Adverse Events
Description
Comparison of the number of device related adverse events in the Test and Control arms. The working hypothesis is that the number of adverse events will be substantially equivalent between the Test and the Control lenses.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Subjective Symptoms
Description
Comparison of subjective symptoms (scored from 0-5) between Test and Control arms. The working hypothesis is that the symptoms will be substantially equivalent between the Test and the Control lenses.
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Prior to being considered eligible to participate in this study, each subject MUST: Be at least 18 years of age as of the date of evaluation. Have: read the Informed Consent, been given an explanation of the Informed Consent, indicated an understanding of the Informed Consent and signed the Informed Consent Form. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments. Be a current contact lens wearer. Possess wearable and visually functional eyeglasses. Be in good general health, based on his/her knowledge. Require spectacle lens powers between +10.00 and -10.00 diopters sphere with no more than 2.5 diopters of spectacle refractive astigmatism and be willing to wear lenses in both eyes. Have manifest refraction visual acuity equal to or better than 0.10 log MAR (20/25 Snellen) in each eye. Exclusion Criteria: Subjects may not be enrolled into the study if ANY of the following apply: Subject is wearing lenses in a mono-vision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may NOT wear mono-vision lenses at any time during the study as it will interfere with the distance visual acuity measurement. Subject appears to exhibit poor personal hygiene (that in the investigator's opinion might prevent safe contact lens wear). Subject is currently or within 30 days prior to this study has been an active participant in another clinical study. Subject is currently pregnant (to the best of the subject's knowledge), is planning a pregnancy within the next 3 months or is lactating. Subject is a member, relative or household member of the office staff, including the investigator(s). Subject has a known sensitivity to ingredients used in contact lens care products or over-the-counter lubricants and artificial tears. Subject has undergone refractive surgery or is currently receiving or has previously received orthokeratology treatment. Subject is aphakic or pseudophakic. Subject has ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome lupus erythematosus, scleroderma, keratoconus or type II diabetes. Subject has 2.5 diopters or great of corneal astigmatism. Use of ocular medications for any reason or systemic medications which might interfere with contact lens wear. A known history of corneal hypoesthesia (reduced corneal sensitivity). Slit lamp findings that would contraindicate contact lens wear, including but not limited to: History of corneal ulcer, corneal infiltrates or fungal infections Corneal scars within the visual axis Pterygium Dry eye symptoms with decrease tear levels and punctate staining ≥ Grade 2 Neovascularization or ghost vessels ≥l.5 mm in from the limbus Seborrhoeic eczema, seborrhoeic conjunctivitis History of papillary conjunctivitis that has interfered with lens wear or a current condition of Grade 2 (Mild) or greater Clinically significant (Grade 3 or 4) anterior segment abnormalities or any infection of the eye, lids, or associated structures. The investigator for any reason considers that it is not in the best interest of the subject to participate in the study. To be eligible to be randomized for study product trial a subject must have ALL of the inclusion criteria and NONE of the exclusion criteria present. To be eligible for lens dispensing, the subject's study device contact lens visual acuity must be equal to or better than 0.20 log MAR (20/32 Snellen) in each eye -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James A Bonafini, BS,MS
Organizational Affiliation
Acuity Polymers
Official's Role
Study Chair
Facility Information:
Facility Name
Ala Mona Advanced Eye Clinic
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96814
Country
United States
Facility Name
Cornea and Contact Lens Institute of Minnesota
City
Edina
State/Province
Minnesota
ZIP/Postal Code
55436
Country
United States
Facility Name
Reed Eye Associates
City
Pittsford
State/Province
New York
ZIP/Postal Code
14534
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Clinical Evaluation of Acuity 200 (Fluoroxyfocon A) RGP Contact Lens

We'll reach out to this number within 24 hrs